BofA moves to No Rating from Underperform on IGM Biosciences (IGMS) after the company announced an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash and a variable non-tradable contingent value right. IGM shares are no longer trading on fundamentals following the deal announcement, the analyst says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Announces Merger with Concentra Biosciences
- IGM Biosciences be acquired by Concentra for $1.247 in cash per share
- IGM Biosciences Faces Nasdaq Non-Compliance Notice
- IGM Biosciences price target lowered to $1 from $2 at Truist
- IGM Biosciences Reports Increased Net Loss Amid Strategic Focus